Jan. 30 at 3:03 PM
Kazia Therapeutics announced compelling preclinical data for NDL2, its potentially first-in-class protein degrader targeting nuclear PD-L1. The Sydney-based oncology company said NDL2 is designed to eliminate nuclear PD-L1, which it has identified as a previously unrecognized driver of immunotherapy resistance and metastatic progression—an intracellular target not addressed by currently approved PD-1/PD-L1 antibody therapies.
In preclinical models of triple-negative breast cancer, NDL2 reduced primary tumor volume by 49% as a monotherapy and by 73% when combined with anti-PD-1 therapy. The combination approach also led to a 50% reduction in lung metastases. Kazia’s CEO, Dr. John Friend, highlighted targeted protein degradation as a transformative opportunity in oncology, noting that NDL2 applies this approach to one of the most clinically validated cancer targets while addressing resistance mechanisms unmet by existing treatments.
$KZIA